industry itself is under a lot of pressure there will be some changes Recognising RFID is only part a new wave of sensor based




Loss of patents cause concern for drug firms

By Tricia Bishop, The Baltimore Sun  
Knight Ridder/Tribune Business News  
886 words  
30 November 2005 
The Baltimore Sun (KRTBN) 
English 
Copyright (C) 2005 KRTBN Knight Ridder Tribune Business News

Nov. 30--The Viagras and Zolofts, the Lipitors and Nexiums are in trouble.

Such blockbuster drugs have earned billions for their creators, but patents are soon to expire on some of the most popular products, opening their formulas to generic copycats and threatening the future profits for drug companies desperate to product the next generation of stars for the medicine cabinet.

That situation underlies this week's announcement by Merck & Co. Inc. that it will layoff 7,000 employees, one-tenth of its workforce, and shutter five of 31 manufacturing sites to save $4 billion through 2010. The company said it would also look to acquire another company to build its product pipeline. Other Pharmaceutical companies, including Pfizer Inc. and Wyeth, have also cut jobs and closed plants during the past year to head off expected declines in profits.

"They've had this productivity problem now since the late 1990s. I think they were hoping it would just go away if they kept doing things the way they had been doing them," said Christopher-Paul Milne, assistant director of the Tufts Center for the Study of Drug Development in Boston. "But for better or for worse, [they're realizing t

12345NextPage





Download links for : << top three maintenance were pressure complacency an use norms applications for nano technology sensors real time human performance modeling >>
"industry itself is under a lot of pressure there will be some changes Recognising RFID is only part a new wave of sensor based"


How to Download
You may need eMule or Bittorrent to download ebook torrents or emule links.

Report Dead Link
Please leave a comment to report dead links, so that someone else may update new links.


Search More...

[share-ebook]industry itself is under a lot of pressure there will be some changes Recognising RFID is only part a new wave of sensor based

Google

Related Books


Books related to :

<< top three maintenance were pressure complacency an use norms applications for nano technology sensors real time human performance modeling

When predetermined thresholds filter back pressure fluid level exceeded accounting business hypnotist medical insurance sales >>


The New York Times rss

    Google

    industry itself is under a lot of pressure there will be some changes Recognising RFID is only part a new wave of sensor based

    Loss of patents cause concern for drug firms

    By Tricia Bishop, The Baltimore Sun  
    Knight Ridder/Tribune Business News  
    886 words  
    30 November 2005 
    The Baltimore Sun (KRTBN) 
    English 
    Copyright (C) 2005 KRTBN Knight Ridder Tribune Business News

    Nov. 30--The Viagras and Zolofts, the Lipitors and Nexiums are in trouble.

    Such blockbuster drugs have earned billions for their creators, but patents are soon to expire on some of the most popular products, opening their formulas to generic copycats and threatening the future profits for drug companies desperate to product the next generation of stars for the medicine cabinet.

    That situation underlies this week's announcement by Merck & Co. Inc. that it will layoff 7,000 employees, one-tenth of its workforce, and shutter five of 31 manufacturing sites to save $4 billion through 2010. The company said it would also look to acquire another company to build its product pipeline. Other Pharmaceutical companies, including Pfizer Inc. and Wyeth, have also cut jobs and closed plants during the past year to head off expected declines in profits.

    "They've had this productivity problem now since the late 1990s. I think they were hoping it would just go away if they kept doing things the way they had been doing them," said Christopher-Paul Milne, assistant director of the Tufts Center for the Study of Drug Development in Boston. "But for better or for worse, [they're realizing t